Ter Woerds Desi K M, Verhoeven Roel L J, van der Heide Stefan M, Verhagen Ad F T M, Aarntzen Erik H J G, van der Heijden Erik H F M
Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Cardio-Thoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
J Thorac Dis. 2023 Feb 28;15(2):291-299. doi: 10.21037/jtd-22-984. Epub 2023 Feb 13.
Early-stage lung cancer is treated with curative intent by surgery or radiotherapy. However, upstaging is frequently seen after surgery in clinical N0 lung cancer patients, and despite curative intent, 2-year recurrence rates of 9-28% are reported. A sentinel lymph node (SLN) procedure could improve the staging accuracy. We explored the feasibility of performing a navigation bronchoscopy based SLN procedure in human lung cancer specimens to optimize procedural parameters and assess a novel injection tool.
Ten lung resection specimens were included and allocated to either peri- or intratumoral injection of a tracer combining Tc-nanocolloid and indocyanine green (ICG) while varying the injection volume. A Pioneer Plus catheter with a pre-angulated 24G needle and an ultrasound (US)-element was used to perform real-time US guided transbronchial injections at multiple locations. Thereafter, single photon emission computed tomography/computed tomography (SPECT/CT)-scanning was performed to image injection depots and to assess their location relative to the tumor.
An average volume of 0.7 mL (range, 0.3-1.2 mL) with an average activity of 89.5 MBq Tc (range, 35.4-188.0 MBq) was injected. Intratumoral injections in non-solid and solid tumors were successful in 100% and 64.3% respectively, while 100% of peritumoral injections in solid tumors were successful. The US-element of the catheter allowed real-time imaging and was able to visualize all tumors and 67.4% of all injections. SPECT/CT-scanning visualized 76.7% of the injection depots.
A navigation bronchoscopy mediated SLN procedure seems technically feasible. The Pioneer Plus is a suitable catheter to place tracer depots at multiple intra-/peri-tumoral sites, while receiving real-time feedback on the needle localization in relation to the tumor. The next step of injections will determine if tracer drainage to the SLN can also be detected on pre- and per-operative imaging.
早期肺癌通过手术或放疗进行根治性治疗。然而,临床N0期肺癌患者术后经常出现分期上调,尽管采用了根治性治疗,但据报道2年复发率为9% - 28%。前哨淋巴结(SLN)手术可提高分期准确性。我们探讨了在人肺癌标本中进行基于导航支气管镜的SLN手术以优化手术参数并评估一种新型注射工具的可行性。
纳入10个肺切除标本,在改变注射体积的同时,将其分配用于瘤周或瘤内注射结合锝纳米胶体和吲哚菁绿(ICG)的示踪剂。使用带有预成角24G针头和超声(US)元件的Pioneer Plus导管在多个位置进行实时超声引导下的经支气管注射。此后,进行单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)扫描以成像注射部位并评估其相对于肿瘤的位置。
平均注射体积为0.7 mL(范围为0.3 - 1.2 mL),平均锝活度为89.5 MBq(范围为35.4 - 188.0 MBq)。非实性和实性肿瘤的瘤内注射成功率分别为100%和64.3%,而实性肿瘤的瘤周注射成功率为100%。导管的超声元件允许实时成像,能够可视化所有肿瘤和67.4%的所有注射。SPECT/CT扫描可视化了76.7%的注射部位。
导航支气管镜介导的SLN手术在技术上似乎是可行的。Pioneer Plus是一种合适的导管,可在多个瘤内/瘤周部位放置示踪剂部位,同时接收关于针头相对于肿瘤定位的实时反馈。下一步注射将确定在术前和术中成像上是否也能检测到示踪剂引流至前哨淋巴结。